Financial StabilityOnce the Udenyca divestment is reflected in Q2, Coherus expects to have ~$250MM in cash on hand, providing about two years of operational runway.
Product AdoptionThe National Comprehensive Cancer Network (NCCN) revised guidelines include Loqtorzi as the preferred regimen.
Strategic TransitionCoherus has made significant positive progress as it has completed its transition to a novel oncology company, including what is considered an attractive sale of its biosimilar business, allowing the company to extinguish its debt and provide funding for the next ~18 months as it executes on driving Loqtorzi sales.